P
DGX icon

Paradiem’s Quest Diagnostics DGX Stock Holding History

Paradiem’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Sell
59,465
-12,015
-17% -$2.36M 2.72% 14
2026
Q1 		$14M Sell
71,480
-7,190
-9% -$1.4M 3.09% 10
2025
Q4 		$13.7M Buy
+78,670
New +$14.3M 3.27% 13

Other funds holding DGX

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Paradiem's DGX Position: Q2 2026 in Review

Paradiem reduced its Quest Diagnostics (DGX) stake by 17% in Q2 2026, selling an estimated $2.36M and leaving 59,465 shares worth $12.6M. The position accounts for 2.72% of the portfolio, ranked #14.

Paradiem first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $14M in Q1 2026. 444 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Paradiem held 59,465 shares of Quest Diagnostics worth $12.6M as of Q2 2026.
  • Paradiem sold 12,015 Quest Diagnostics shares in Q2 2026, an estimated $2.36M.
  • Quest Diagnostics made up 2.72% of Paradiem's portfolio in Q2 2026, its #14 holding.
  • Paradiem first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • Paradiem's Quest Diagnostics position peaked at $14M in Q1 2026.
  • 444 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Paradiem's 13F filing for Q2 2026, filed 14 Jul 2026.